Carregant...
Agomelatine in the Treatment of Major Depressive Disorder: An Assessment of Benefits and Risks
Agomelatine (AGM) was approved for the treatment of major depressive disorder (MDD) in adults by the European Medicines Agency (EMA) in February 2009. It is an analogue of melatonin and features a unique pharmacodynamic profile with agonism on both types of melatonergic receptors (MT1/MT2) and antag...
Guardat en:
| Publicat a: | Curr Neuropharmacol |
|---|---|
| Autor principal: | |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Bentham Science Publishers
2014
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4243030/ https://ncbi.nlm.nih.gov/pubmed/25426008 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2174/1570159X12999140619122914 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|